Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.
You may also be interested in...
Aegerion’s Lojuxta Submission To Germany's IQWIG Disappoints
IQWIG’s review is now open for consultation, with Germany's top HTA body the G-BA expected to make a final decision about the benefits of the ultra-orphan in December.
Smallpox Discovery Prompts FDA Action Plan; Move To White Oak Unchanged
FDA scientist’s discovery of decades-old vials of smallpox at lab on NIH campus are a reminder of the unsettled debate on whether governments should keep smallpox stock to aid development of antivirals.
U.S. Biotech Ariad Builds European Presence For Imminent Iclusig Launches
A new Swiss HQ for its European business and country-focused medical marketing teams are part of U.S.-based Ariad's solo push into the region, to be followed by development of new indications and new cancer-targeted therapies.